5/7
09:00 am
adct
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/7
08:01 am
adct
ADC Therapeutics SA (NYSE: ADCT) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
ADC Therapeutics SA (NYSE: ADCT) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
5/6
08:48 am
adct
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
High
Report
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/6
07:39 am
adct
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants [Yahoo! Finance]
High
Report
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants [Yahoo! Finance]
5/6
07:30 am
adct
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
Low
Report
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
5/6
06:15 am
adct
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
High
Report
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
5/6
06:10 am
adct
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
High
Report
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
5/6
06:04 am
adct
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma [Yahoo! Finance]
High
Report
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma [Yahoo! Finance]
5/6
06:00 am
adct
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
High
Report
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
5/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Low
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
5/1
07:00 am
adct
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
Medium
Report
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
4/16
08:30 am
adct
ADC Therapeutics Accelerates R&D with Genedata Biologics
Medium
Report
ADC Therapeutics Accelerates R&D with Genedata Biologics
4/15
08:11 am
adct
ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
4/5
10:25 am
adct
ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
ADC Therapeutics SA (NYSE: ADCT) had its "buy" rating re-affirmed by analysts at Guggenheim.
4/4
07:07 am
adct
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Yahoo! Finance]
Medium
Report
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Yahoo! Finance]
4/4
07:00 am
adct
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Medium
Report
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
4/3
07:09 am
adct
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 [Yahoo! Finance]
Low
Report
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 [Yahoo! Finance]
4/3
07:00 am
adct
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
Low
Report
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
4/1
04:21 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan [Yahoo! Finance]
Low
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan [Yahoo! Finance]
4/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Low
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
3/28
08:00 am
adct
ADC Therapeutics SA (NYSE: ADCT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $11.00 price target on the stock.
Low
Report
ADC Therapeutics SA (NYSE: ADCT) is now covered by analysts at Guggenheim. They set a "buy" rating and a $11.00 price target on the stock.
3/19
09:40 am
adct
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) [Seeking Alpha]
Low
Report
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) [Seeking Alpha]
3/18
03:06 pm
adct
ADC Therapeutics SA (NYSE: ADCT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.
Low
Report
ADC Therapeutics SA (NYSE: ADCT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.
3/16
08:57 am
adct
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results [Yahoo! Finance]
High
Report
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results [Yahoo! Finance]
3/13
10:33 am
adct
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]